# RENAL FAILURE

# ACUTE KIDNEY INJURY (AKI)

## 定義 (_KDIGO_ 2012;2:1)

• Stages in ICU correspond to ↑ hospital mortality and LOS (_Crit Care Med_ 2009;37:2552)

Stage 1: Cr ≥0.3 mg/dL in 2d or ↑ Cr ≥50%, or UOP <0.5 mL/kg/h for ≥6h

Stage 2: ↑ Cr 2–3x baseline in 7d or UOP <0.5 mL/kg/h for ≥12h

Stage 3: ↑ 3x baseline in 7d, UOP <0.3 mL/kg/h for ≥24h, anuria ≥ 12h, or Cr >4

• _Cannot_ estimate GFR using Cr in setting of AKI or ∆’ing Cr (requires steady state)

## Workup (_NEJM_ 2014;371:55)

• **H&P:** meds, contrast, or other nephrotoxins; ↓ PO intake, HoTN, infxn/sepsis; trauma, myalgias; BPH/retention. Search for insult 24–48 hr prior ↑ Cr. VS, vol status, rash.

• **Urine evaluation:** output, urinalysis, **sediment**, electrolytes, and osmolality

• **Fractional excretion Na (FENa)** = (UNa/PNa)/(UCr/PCr); if diuretic, ✔ FEUN\=(UUN/PUN)/(UCr/PCr)

• Renal U/S or CT: 排除 obstruction & cortical atrophy in chronic kidney disease

• Serologies (if indicated): see “Glomerular Disease”

• Renal biopsy (microscopy, IF, and EM): if etiology unclear (esp. if proteinuria/hematuria). Relative contraindic.: SBP>150, ASA/NSAID, anticoag, cirrhosis. DDAVP if GFR <45.

<table><colgroup><col> <col> <col></colgroup><tbody><tr><td colspan="3"><p><b>原因 and Diagnosis of Acute Kidney Injury</b> <span>(</span><span><i>Lancet</i></span> <span>20</span><span>1</span><span>2;380:756)</span></p></td></tr><tr><td colspan="2"><p><b>原因</b></p></td><td><p><b>UA, Sediment, Indices</b></p></td></tr><tr><td><p><b>Prerenal</b></p></td><td><p>↓ <b>Effective arterial volume</b> <span>(</span><span><i>NEJM</i></span> <span>2007;357:797)</span> Hypovolemia, ↓ CO (CHF), ↓ oncotic pressure (cirrhosis, nephrotic), vasodilation (sepsis)</p><p>Δ <b>local renal perfusion:</b> NSAIDs, ACEI/ARB, contrast, calcineurin inhib, HRS, hyperCa</p><p><b>Large vessel:</b> RAS (bilateral + ACEI), VTE, dissection, abd compart. synd. (renal vs. compress), vasculitis</p></td><td><p>Bland</p><p>Transparent hyaline casts</p><p>FE<sub>Na</sub> &lt;1%, BUN/Cr &gt;20</p><p>FE<sub>UN</sub> ≤35%</p></td></tr><tr><td rowspan="4"><p><b>Intrinsic</b></p></td><td><p><b>Acute tubular necrosis (ATN)</b></p><p><i>Severe ischemia, sepsis, CIN</i> (↓ RBF + toxin)</p><p><i>Toxins</i></p><p>Drugs: vanc, AG, cisplatin, foscarnet, HES (starch), IVIG, pentamidine, amphotericin, tenofovir</p><p>Pigments: Hb, myoglobin <span>(</span><span><i>NEJM</i></span> <span>2009;36</span><span>1</span><span>:62)</span></p><p>Monoclonal: Ig light chains <span>(</span><span><i>Blood</i></span> <span>20</span><span>1</span><span>0;</span><span>11</span><span>6:</span><span>1</span><span>397)</span></p><p>Crystals: UA, ACV, MTX, indinavir, oral NaPO<sub>4</sub></p></td><td><p>Pigmented granular muddy brown casts in ~75%</p><p>± RBCs &amp; protein from tubular damage</p><p>FE<sub>Na</sub> &gt;2%, BUN/Cr &lt;20 (except pigment, CIN)</p><p>FE<sub>UN</sub> &gt;50%</p></td></tr><tr><td><p><b>Acute interstitial nephritis (AIN)</b></p><p><i>Allergic:</i> β-lactams, sulfa drugs, NSAIDs, PPIs</p><p><i>Infection:</i> pyelo, viral, legionella, TB, leptospirosis</p><p><i>Infiltrative:</i> sarcoid, lymphoma, leukemia</p><p><i>Autoimmune:</i> Sjögren’s, TINU syndrome, IgG4, SLE</p></td><td><p>WBCs, WBC casts, ± RBCs with neg UCx</p><p>⊕ urine eos in 抗生素</p><p>⊕ lymphs in NSAIDs</p></td></tr><tr><td><p><b>Small-med vessel:</b> chol emboli, PAN, TMAs (TTP, HUS, atypical HUS, DIC, preeclampsia, APS, malignant HTN, scleroderma renal crisis)</p></td><td><p>± RBCs</p><p>⊕ urine eos in chol emboli</p></td></tr><tr><td><p><b>Glomerulonephritis</b> (see “Glomerular Disease”)</p></td><td><p>Dysmorphic RBCs, RBC casts</p></td></tr><tr><td><p><b>Post</b></p></td><td><p><b>Bladder neck:</b> BPH, prostate cancer, neurogenic bladder, anticholinergic meds</p><p><b>Ureteral</b> (bilateral or unilateral in single kidney): malig, LAN, retroperitoneal fibrosis, nephrolithiasis</p></td><td><p>Bland ± non-dysmorphic RBCs, WBC, crystals</p></td></tr></tbody></table>

## General 治療 (_CJASN_ 2008;3:962)

• Prerenal: isotonic IVF ≈ alb (_NEJM_ 2004;350:22). May be benefit to balanced crystalloids (LR) in ICU (_NEJM_ 2018;378:829).

• Avoid nephrotoxic insults (meds and contrast); renally dose medications

• Optimize hemodynamics (both MAP & CO) and maintain euvolemia (_NEJM_ 2007;357:797)

• _No_ benefit to dopamine (_Annals_ 2005;142:510), diuretics (_JAMA_ 2002;288:2547), or mannitol

## Managing complications

• May take 1–3 wk to recover from ATN; anticipate volume overload, ↑ K, ↑ PO4, acidosis

• Episodes of AKI ↑ risk of CKD progression, even after recovery (_NEJM_ 2014;371:58)

• Indications for urgent dialysis (when condition refractory to conventional therapy)

* Acid-base disturbance: refractory acidemia

* Electrolyte disorder: hyperK; hyperCa, hyperPO4, tumor lysis syndrome

* Intoxications ([http://www.extrip-workgroup.org/](http://www.extrip-workgroup.org/)): Poison Control (1-800-222-1222)

Indicated for: methanol, ethylene glycol, metformin, Li, valproic acid, salicylates, barbiturates, theophylline, thallium

Consider for: carbamazepine, APAP, dig (Rx Digibind), dabigatran, (Rx idarucizumab)

* Overload: refractory hypervolemia → hypoxemia (eg, CHF)

* *Uremia: pericarditis, encephalopathy, bleeding

• No mortality benefit to early initiation of RRT (_NEJM_ 2016;375:122 & _Jama_ 2018;379:1431)

# DISEASE SPECIFIC MANAGEMENT

## Acute interstitial nephritis (AIN) (_CJASN_ 2017;12:2046)

• Commonly drug-induced: β-lactams, sulfa drugs, NSAIDs, PPIs, quinolones, allopurinol

• If suspected, prompt removal of offending drug; ? early steroids within 7d of dx

## Cardiorenal syndrome (CRS) (_CJASN_ 2017;12:1624)

• Multifactorial pathophys including: 1) ↓ CO, 2) ↑ renal venous congestion, 3) ↑ RAAS

• Bidirectionality: acute CHF → AKI, and oliguric AKI can worsen CHF (_JACC_ 2008;52:1527)

• Rx: **IV loop diuretics** (bypass gut edema; dosing below); no diff. between high vs. low dose and bolus vs. gtt (_NEJM_ 2011;364:797). No 臨床benefit: dopa, nesiritide, ultrafilt.

• Prognosis: 7% ↑ mortality a/w each 10 mL/min ↓ eGFR in ADHF (_JACC_ 2006;47:1987)

## Contrast-induced acute kidney injury (CIAKI) (_NEJM_ 2019;380:2146)

• Risk factors: CKD, DM, CHF, age, hypotension, ↑ contrast volume (_JACC_ 2004;44:1393)

• AKI 24–48 h post contrast, peaks 3–5 d, resolves 7–10 d (consider chol emboli if does not)

• Prevention: consider if eGFR <60 (espec. with proteinuria), DM, MI, HoTN (_CJASN_ 2013;8:1618)

**Isotonic IV fluids:** data mixed, but may be helpful if high risk (_Int Med_ 2014;53:2265; _Lancet_ 2017;389:1312). No benefit to NaHCO3 over NaCl (_NEJM_ 2018;378:603).

Outpatients: 3 mL/kg/h × 1h prior, 1–1.5 mL/kg/h × 6h after (_JAMA_ 2004;291:2328)

Inpatients: 1 mL/kg/h × 6–12 h pre, intra, post-procedure (_Lancet_ 2014;383:1814)

Hold ACEI/ARB (_AJKD_ 2012;60:576), NSAIDs, diuretics. Min. contrast & use iso-osmolar.

No benefit to NAC (_NEJM_ 2018;378:603) or preemptive RRT (_Am J Med_ 2012;125:66)

• Nephrogenic systemic fibrosis: fibrosis of skin, joints, internal organs ~2–4 wk post gado exposure in CKD 4–5 (_JACC_ 2009;53:1621). Postgado HD encouraged, though limited data.

## Diabetic nephropathy (_NEJM_ 2016;375:2096)

## Hepatorenal syndrome (HRS; see “Cirrhosis”; _AJKD_ 2013;62:1198)

• Albumin + _either_ IV vasopressors (norepi, terlipressin) _or_ octreotide & midodrine

## Obstructive diseases

• Dx: renal U/S if undifferentiated or CT abd/pelvic (I–) if suspect nephrolithiasis

• Rx: Foley if urethra vs. perc. nephrostomy if above ureters (eg, stones), tamsulosin/finasteride

• Watch for post-obstructive diuresis after relieving blockage, replace ½ UOP with ½ NS.

Hemorrhagic cystitis (rapid ∆ in size of bladder vessels); avoid by decompressing slowly.

## Polycystic kidney disease (_NEJM_ 2004;350:151; 2008;359:1477; 2017;377:1988)

• Mostly AD _PKD1/PKD2_ mutations → renal cysts. PKD1 (85%) younger-onset ESRD.

• Rx: hydration, low-salt diet; tolvaptan reduces GFR decline. Family genetic screening.

## Rhabdomyolysis (_NEJM_ 2009;361:62)

• Pathophys: myoglobin-induced oxidant injury, vasoconstriction, myoglobin precipitation & pre-renal (extravasation). Can lead to ↓ Ca, ↑ K, and ↑ PO4.

• Diagnosis: UA ⊕ for heme but 0 RBCs (ie, myoglobinuria)

• Risk of AKI when CK >20,000. Rhabdo and mortality risk score: _JAMA Int Med_ 2013;173:1821.

• Aggressive IVF (tailor IVF to target UOP ~3 mL/kg). If urine pH <6.5, consider NaHCO3 ✔ K & Ca frequently, trend CK. Monitor for compartment syndrome.

## Scleroderma renal crisis (_Nature Neph_ 2016;12:678)

• 5–20% diffuse cutaneous SSc with narrowing glomerular vessels. Sx: renal failure, severe HTN, encephalopathy. Rx: max ACEi for BP control.

## Thrombotic microangiopathies (TMAs): _see “Hematology”_

# CHRONIC KIDNEY DISEASE (CKD)

## 定義 and 原因 (_Lancet_ 2012;379:165; _JAMA_ 2015;313:837)

• **GFR** <60 for ≥3 mo _and_/_or_ **kidney damage** (albuminuria, structural abnormality)

• Prevalence 15% in U.S.

• Albuminuria predicts all-cause & CV mortality, CKD progression (_NEJM_ 2004;351:1296)

• Cr poor estimate of GFR, use equation ([www.kidney.org/professionals/KDOQI/gfr\_calculator.cfm](http://www.kidney.org/professionals/KDOQI/gfr_calculator.cfm))

CKD-EPI preferred over MDRD because less likely to underestimate at normal GFRs

cystatin-C–based formulae perform better than Cr-based (_NEJM_ 2012;367:20)

• 原因: DM (45%), HTN/RAS (27%), glomerular (10%), interstitial (5%), PKD (2%) (_NEJM_ 2008;359:1477; _AJKD_ 2019;73:A7), congenital, drugs, myeloma (_JAMA_ 2009;302:1179), repeated insults (eg, Mesoamerican nephropathy _AJKD_ 2018;72:469)

• Progression to ESRD: kidney failure risk equation (_JAMA_ 2016;315:164)

<table><colgroup><col> <col> <col></colgroup><tbody><tr><td colspan="3"><p><b>Stages of CKD</b> <span>(</span><span><i>Kid Int</i></span> <span>20</span><span>1</span><span>3;3[Suppl]:5)</span></p></td></tr><tr><td><p><b>GFR Stage</b></p></td><td><p><b>GFR</b> mL/min/1.73 m<sup>2</sup></p></td><td><p><b>Goals</b></p></td></tr><tr><td><p>1 (nl or ↑ GFR)</p></td><td><p>&gt;90</p></td><td><p>Dx/Rx of underlying condition &amp; comorbidities, slow progression; cardiovascular risk reduction</p></td></tr><tr><td><p>2 (mild)</p></td><td><p>60–89</p></td><td><p>Estimate progression</p></td></tr><tr><td><p>3a (mild-mod)</p></td><td><p>45–59</p></td><td><p>Evaluate and treat complications</p></td></tr><tr><td><p>3b (mod-severe)</p></td><td><p>30–44</p></td><td><p>Evaluate and treat complications</p></td></tr><tr><td><p>4 (severe)</p></td><td><p>15–29</p></td><td><p>Prepare for renal replacement therapy (RRT)</p></td></tr><tr><td><p>5 (kidney failure)</p></td><td><p>&lt;15 or dialysis</p></td><td><p>Dialysis if uremic/volume overload; Tx</p></td></tr><tr><td colspan="3"><p><b>Albuminuria stage</b> based on albuminuria (mg/d) or spot urine alb (mg) to Cr (g) ratio</p><p>Stages: A1 = &lt;30 (normal/mild); A2 = 30–300 (moderate); A3 = &gt;300 (severe)</p></td></tr></tbody></table>

<table><colgroup><col> <col></colgroup><tbody><tr><td colspan="2"><p><b>Signs and Symptoms of Uremia</b> <span>(</span><span><i>NEJM</i></span> <span>20</span><span>1</span><span>8;379:669)</span></p></td></tr><tr><td><p>General</p></td><td><p>Nausea, anorexia, malaise, uremic fetor, metallic taste, hypothermia</p></td></tr><tr><td><p>Skin</p></td><td><p>Uremic frost (white crystals in &amp; on skin), pruritus, calciphylaxis</p></td></tr><tr><td><p>Neurologic</p></td><td><p>Encephalopathy (Δ MS, ↓ memory &amp; attention), seizures, neuropathy, impaired sleep, restless leg syndrome</p></td></tr><tr><td><p>Cardiovascular</p></td><td><p>Pericarditis, atherosclerosis, HTN, CHF, cardiomyopathy (LVH)</p></td></tr><tr><td><p>Hematologic</p></td><td><p>Anemia, bleeding (due to platelet dysfunction and Epo deficiency)</p></td></tr><tr><td><p>Metabolic</p></td><td><p>↑ K, ↑ PO<sub>4</sub>, acidosis, ↓ Ca, 2° hyperparathyroidism, osteodystrophy</p></td></tr></tbody></table>

## Complications & 治療 (KDIGO 2013)

• **General:** renal referral when GFR <30 or proteinuria, access planning (avoid subclavian lines, preserve an arm by avoiding phlebotomy, BP measurements, IVs)

• **CV risk reduction:** consider usual preventive Rx including statin, βB, etc.

• **Dietary restrictions:** Na (if HTN), K (if oliguric or hyperkalemic), PO4, mod protein.

• **Diabetes:** strict glc control; SGLT2i slow CKD progression (_NEJM_ 2017;377:1765 & 2019;380:2295)

• **BP control:** goal <130/80, a/w ↓ mortality (_NEJM_ 2015;373:2103; _JASN_ 2017;28:2812). ACEI or ARB (NEJM 2004;351:1952), not both (_NEJM_ 2013;369:1892). For outPts, ✔ Cr & K in 1–2 wk, d/c if Cr ↑ 30% or K >5.4 (after dietary Δ & loop diuretic).

• **Metabolic acidosis:** sodium bicarbonate or sodium citrate if low HCO3 (_JASN_ 2015;26:515)

• **Hyperkalemia:** 2-g K diet, see “Potassium Homeostasis”

• **Anemia:** goal Hb 10–11.5 g/dL, worse outcomes if target higher (_NEJM_ 2009;361:2019)

epoetin (start 80–120 U/kg SC, divided 3×/wk) or darbepoetin (0.75 mg/kg q 2wk)

iron supplementation to keep transferrin sat >20% (often given IV in HD 病人)

• **Uremic bleeding:** desmopressin (dDAVP) 0.3 μg/kg IV or 3 μg/kg intranasally

• **2**° **hyperPTH:** ↑ PO4, ↓ Ca, ↓ calcitriol, ↑ FGF-23 → ↑ PTH → renal osteodystrophy

![](https://i.imgur.com/6ktL9o9.jpg)

Phosphorus binders (_take with meals!_) (_NEJM_ 2010;362:1312)

Consider sevelamer first, Ca acetate & lanthanum other options. Non-Ca–based binders a/w ↓ mort. compared to Ca-based (_Lancet_ 2013;382:1268).

If PTH above goal then start vit. D (if 25-(OH)D <30) or 1,25-(OH)D analogue (calcitriol); stop if ↑ Ca (_AJKD_ 2009;53:408)

Cinacalcet (parathyroid Ca-sensing receptor agonist) if ↑ PTH despite phosphorus binders ± vit. D analogue (_CJASN_ 2016;11:161); consider parathyroidectomy

• **Calciphylaxis** (calcific uremic arteriopathy, _NEJM_ 2018;378:1704)

Pathophys: calcification of media in dermal small- to med-sized blood vessels & SC fat → ischemia and skin necrosis with painful lesions (_NEJM_ 2007;356:1049)

Risk factors: ESRD, ♀>♂, DM, vit K def, obesity, warfarin, local trauma, thrombophilias

Dx: skin bx, but limitations (_Kidney Int_ 2018;94:390); bone scan used in support of dx

Rx: ↓ risk factors, wound care/surgical debridement, Na thiosulfate (_CJASN_ 2013;8:1162), manage hyperPTH, no vit D & Ca, NOACs > warfarin, pain control, palliative care

Prognosis: 60% 1-y mortality in ESRD 病人 (_AJKD_ 2015;66:133)

• **Anticoag:** ESRD at ↑ bleed risk; if using DOAC, consider apixiban > rivaroxaban > dabigatran due to protein binding/renal clearance (_JASN_ 2017;28:2241)

• **Transplant evaluation**

# DIURESIS

## General considerations

• ↑ Na & H2O excretion for 治療 of HTN or edema in CHF, renal failure, and cirrhosis

• Daily wt most effective method of documenting successful diuresis

## Loop diuretics 
> (_NEJM_ 2017;377:1964)

• **Drugs:** furosemide (Lasix), torsemide, bumetanide (Bumex), ethacrynic acid

• **Mech:** inhib NaK2Cl cotransporter in thick ascending limb (ThAL, site of 25% Na reabsorp) → ↓ medullary osmotic gradient & ↓ free H2O reabsorption via ADH

Transient venodilation may aid in pulmonary congestion (_NEJM 1_973;288:1087)

Response is fxn of amt of drug excreted; ∴ ↑ dose needed in renal insufficiency, CHF

Sigmoidal dose response curve; ∴ ↑ dose until induce diuresis, ↑↑ dose beyond that point yields diminishing returns compared with ↑ frequency of dosing

• **Dosing:** bioavailability PO furosemide ~50%, PO torsemide & bumetanide ~90%

40 mg IV = 80 mg PO Lasix = 20 mg PO/IV torsemide = 1 mg IV/PO bumetanide

Dose furosemide bid-qid; qd dosing can yield initial diuresis, but then anti-natriuresis. Cont. vs. bolus IV similar in acute CHF (_NEJM_ 2011;364:797). Ethacrynic acid if sulfa allergy.

? ↑ diuresis with co-administration of albumin if ↓ serum albumin (_Crit Care Med_ 2005;33:1681)

• **Adverse effects:** ↑ Na, ↓ K, ↓ Mg, ↓ Ca, hyperuricemia, ototoxicity, hypersensitivity (sulfa)

## Thiazide diuretics (_JASN_ 2017;28:3414)

• **Drugs:** hydrochlorothiazide (HCTZ), chlorothiazide (Diuril), metolazone (Zaroxolyn)

• **Mech:** inhib Na-Cl cotransporter in the distal convoluted tubule (DCT); 5% Na reabsorp

> synergistic with loop diuretic, esp. if chronic loop use

↓ effect when GFR <30, _except metolazone_, which is still effective in renal insufficiency

• **Dosing:** give 30 min prior to loop diuretic

• **Adverse effects:** ↓ Na, ↓ K, ↓ Mg, ↑ Ca, HLD, pancreatitis, ↑ glc, hypersensitivity

## K-sparing diuretics (_NEJM_ 2017;377:1964)

• **Drugs:** spironolactone (Aldactone), amiloride, triamterene, eplerenone

• **Mech:** ↓ Na reabsorption (~1%) in collecting duct (amiloride/triamterene inhibit principal cell Na channel \[ENaC\]; spironolactone/eplerenone inhibit mineralocorticoid receptor).

Relatively weak natriuretic activity, useful in combination with thiazide or in cirrhosis.

• **Adverse effects:** ↑ K (esp. with ACEI), metabolic acidosis, gynecomastia (spironolactone)

<table><colgroup><col> <col></colgroup><tbody><tr><td colspan="2"><p><b>Approach to Diuresis</b> <span>(if inadequate diuresis, go to next step)</span></p></td></tr><tr><td><p><b>Step</b></p></td><td><p><b>Action</b></p></td></tr><tr><td><p>1</p></td><td><p><b>Loop diuretic PO:</b> ✔ response at 1–3 h, redose at 2× prior dose if needed</p></td></tr><tr><td><p>2</p></td><td><p><b>Add thiazide diuretic PO</b> (potentiates response to loop diuretic)</p></td></tr><tr><td><p>3</p></td><td><p><b>Loop diuretic IV:</b> bolus bid–qid ± thiazide (<i>may start here if inPt</i>) ↑ dose with ↑ Cr; initial effective IV Lasix dose ≈ 30 × Cr (ie, if Cr = 4 → 120 mg IV)</p></td></tr><tr><td><p>4</p></td><td><p><b>Loop diuretic infusion:</b> bolus + continuous IV infusion ± thiazide (PO or IV)</p></td></tr><tr><td><p>5</p></td><td><p><b>RRT:</b> consider ultrafiltration, CVVH, or HD</p></td></tr></tbody></table>

## Disease state specific regimens

• Renal insufficiency: loop diuretic (↑ dose to achieve effective delivery to ThAL) ± thiazide

• CHF: loop diuretic (↑ frequency over ↑ dose), IV for gut edema + thiazide (watch K & Mg)

• Nephrotic syndrome: urinary albumin binds secreted loop diuretic, use 2–3× normal dose

• Cirrhosis: spironolactone (blocks 2° hyperaldosteronism) + Lasix in 2.5:1 ratio

• Severe metabolic alkalosis: acetazolamide & treat underlying cause

# RENAL REPLACEMENT AND DIALYSIS

## General

• Acute indications: see “AKI”; choices CVVH vs. HD

• Chronic indications: timing of RRT initiation should factor in Pt 生活品質, uremic sx, risk of development of urgent/acute indications; modalities PD vs. HD (no clear diff in outcomes)

• Outcomes of ESRD: death from CVD (50%), infxn (30%), withdrawal of care (20%)

![](https://i.imgur.com/3brG9cy.jpg)

\*Disequilibrium syndrome: sx cerebral edema due to H2O shifts after urea removal

## Hemodialysis (HD) (_NEJM_ 2010;363:1833)

• Solute removal across _semipermeable_ membrane, countercurrent blood & dialysate flow

Volume removal: Na/H2O ultrafiltered via transmembrane pressure (TMP) gradient

Solutes: Cr, urea, K diffuse from blood → dialysate, HCO3 from dialysate → blood

Solute removal inversely proportional to size ∴ effective removal of K, urea, Cr, not PO4

• 6× vs. 3×/wk improved HTN, LV mass, 生活品質, but ↑ vasc issues (_NEJM_ 2010;363:2287); with 3×/wk HD, ↑ mortality risk during 2-d interval (Sa–Tu or Fri–Mo) (_NEJM_ 2011;365:1099)

• Fever with catheter: empiric 抗生素 (vanc + GNR coverage qHD). GPC > GNR > mixed/fungal. Remove/replace catheter (depends on organism), “lock” 抗生素 (_JASN_ 2014;25:2927).

• Central vein stenosis: assoc. with longer HD duration, tunneled catheters. HeRO grafts bypass subclavian stenosis with flow into central vein (_J Vasc Access_ 2016;17:138).

<table><colgroup><col> <col> <col></colgroup><tbody><tr><td colspan="3"><p><b>Vascular Access</b></p></td></tr><tr><td></td><td><p><b>Advantages</b></p></td><td><p><b>Disadvantages</b></p></td></tr><tr><td><p><b>AV fistula</b></p></td><td><p>Highest patency</p><p>Lowest risk of bacteremia</p><p>Lowest mortality <span>(</span><span><i>JASN</i></span> <span>20</span><span>1</span><span>3;24:465)</span></p></td><td><p>Long maturation time (2–6 mo)</p><p>Primary nonfunction (20%)</p></td></tr><tr><td><p><b>AV graft</b></p></td><td><p>Easier to create than AVF</p><p>Maturation time (2–3 wk)</p></td><td><p>Poor 1° patency, often requiring thrombectomy or angioplasty</p></td></tr><tr><td><p><b>Catheter</b></p></td><td><p>Immediate use</p><p>Use as bridge to AVF/AVG</p></td><td><p>Highest risk of bacteremia</p><p>↓ blood flow → ↓ HD efficiency</p></td></tr></tbody></table>

## Continuous veno-venous hemofiltration (CVVH) (_NEJM_ 2012;367:26)

• _Hemofiltration_ rather than dialysis. Blood under pressure passes down one side _highly permeable_ membrane filtering H2O and solutes via TMP gradient (convective clearance); filtrate discarded. Replacement fluid infused (solute concentration similar to plasma, except no urea, Cr, PO4). Fluid balance by adjusting filtrate/replacement fluid.

• Replacement fluid rate determines clearance. Choice of replacement fluid buffer:

>  HCO3 (+ heparin to prevent clotting, although can be run heparin-free)

**citrate:** hepatically metabolized to HCO3, ∴ cannot be given in cirrhosis/liver failure. Provides anticoag within machine via Ca chelation. Citrate toxicity: ↓ iCa but 正常/ ↑ serum Ca and AG met acidosis.

Dose adjust for solute and volume removal (_AJKD_ 2016;68:645)

• Other CRRT modalities: CVVHD (dialysis), CVVHDF (filtration & dialysis) (_AJKD_ 2016;68:645)

• Benefits compared with HD: ↓ gross fluid shift (preferred in HoTN), but slower clearance of solutes and toxins

## Peritoneal dialysis (PD) (_JAMA_ 2017;317:1864)

• Fluid removed via convection using oncotic pressure (eg, dextrose). ↑ concentrations and dwell times removes more fluid (less as glc equilibrates).

• PD fluid: dextrose (1.5%, 2.5%, or 4.25%), buffer (lactate), Na+, Ca2+, Mg2+

• infuse 10 min, dwell 90 min–5.5 h, drain 20 min; exchanges done manually or using cycler at night (automated or cont. ambulatory peritoneal dialysis APD, CAPD)

• PD peritonitis: abd pain & cloudy drainage (WBC >100 & >50% PMNs). 60–70% GPC, 15– 20% GNR. Rx: 抗生素 IV or in PD, catheter removal for certain org (yeast, _Pseudomonas_).

• Sclerosing peritonitis, a rare long-term complication (_NEJM_ 2002; 347:737)

• Hyperglycemia: exacerbated by inflammation, long dwell times, and higher \[glucose\]

• Benefits: lower cost, independence, preservation of residual kidney function. No Δ mortality vs. HD (_AJKD_ 2018;71:344).

## Kidney transplantation 
> (_Med Clin N Am_ 2016;100:435)

• Refer when GFR <20. Contraindic: active malig, infxn, ischemia, noncompl, subst use

• 5-yr survival: living donor 91%; deceased donor 70–84% (_AJKD_ 2016;23:281). Donors have minor ↑ risk of ESRD (_Am J Transplant_ 2014;14:2434).

• Immunosuppression: calcineurin inhib (tacrolimus>CsA) or CTLA4 inhib (belatacept) (_NEJM_ 2016;374:333), antimetabolite (MMF>AZA), prednisone, mTOR inhib (sirolimus) if others contraindicated

• Rejection: Ab (ABMR) or T-cell mediated (TCMR), a/w poor graft survival; BANFF criteria (_Am J Transplant_ 2018;18:293). Rx options: ↑ immunosupp., pulse steroids, IVIG, rituximab.

• Late renal dysfxn: usual AKI causes + calcineurin tox, rejection (_NEJM_ 2010;363:1451), BK virus, recurrence of 1° disease; usual workup + immunosupp levels, donor-specific antigen (DSA), BK virus load, U/S, then bx if no other cause (_CJASN_ 2008;3:S56; _CJASN_ 2011;6:1774)

• ↑ infxn (incl opportunistic such CMV, JC, BK viruses; _CJASN_ 2012;7:2058) & cancer (PTLD)

• ↑ CVD risk due to HTN (calcineurin inhib, RAS), DM & dyslipidemia (immunosupp meds)
